- Home
- CSTL vs ABCL Comparison
CSTL vs ABCL Comparison
Compare CSTL & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- ABCL
- Stock Information
- Founded
- CSTL 2007
- ABCL 2012
- Country
- CSTL United States
- ABCL Canada
- Employees
- CSTL N/A
- ABCL N/A
- Industry
- CSTL Medical Specialities
- ABCL Biotechnology: Pharmaceutical Preparations
- Sector
- CSTL Health Care
- ABCL Health Care
- Exchange
- CSTL Nasdaq
- ABCL Nasdaq
- Market Cap
- CSTL 848.1M
- ABCL 841.8M
- IPO Year
- CSTL 2019
- ABCL 2020
- Fundamental
- Price
- CSTL $27.14
- ABCL $3.03
- Analyst Decision
- CSTL Strong Buy
- ABCL Buy
- Analyst Count
- CSTL 6
- ABCL 3
- Target Price
- CSTL $39.67
- ABCL $8.50
- AVG Volume (30 Days)
- CSTL 301.1K
- ABCL 2.6M
- Earning Date
- CSTL 11-04-2024
- ABCL 02-18-2025
- Dividend Yield
- CSTL N/A
- ABCL N/A
- EPS Growth
- CSTL N/A
- ABCL N/A
- EPS
- CSTL 0.21
- ABCL N/A
- Revenue
- CSTL $311,878,000.00
- ABCL $32,962,000.00
- Revenue This Year
- CSTL $51.36
- ABCL N/A
- Revenue Next Year
- CSTL N/A
- ABCL $36.56
- P/E Ratio
- CSTL $131.77
- ABCL N/A
- Revenue Growth
- CSTL 62.43
- ABCL N/A
- 52 Week Low
- CSTL $16.97
- ABCL $2.34
- 52 Week High
- CSTL $35.84
- ABCL $6.06
- Technical
- Relative Strength Index (RSI)
- CSTL 39.78
- ABCL 53.74
- Support Level
- CSTL $26.99
- ABCL $2.62
- Resistance Level
- CSTL $28.08
- ABCL $2.96
- Average True Range (ATR)
- CSTL 1.51
- ABCL 0.16
- MACD
- CSTL -0.15
- ABCL -0.00
- Stochastic Oscillator
- CSTL 22.78
- ABCL 66.69
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.